Its February 13 call with analysts was a first for Regeneron Pharmaceuticals Inc., the 22-year-old Tarrytown, NY-based biotech that just launched its first major drug. Sales of the drug, Eylea (aflibercept), totaled $24.8 million in the first six weeks on the market; thus, the company would be doubling its 2012 guidance for the drug from $140 million to $160 million to $250 million to $300 million in revenues, co-founder and CEO Leonard Schleifer, MD, PhD, announced.
“2011 was truly a transformational year for us. It was the year we advanced our vision of becoming not only...